American Portfolios Advisors Marker Therapeutics, Inc. Transaction History

American Portfolios Advisors

$2.36 Trillion
Q3 2022

A detailed history of American Portfolios Advisors transactions in Marker Therapeutics, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 21,170 shares of MRKR stock, worth $70,284. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,170

Holding current value

$70,284

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Mar 17, 2023	BUY	$0.3 - $3.73 $6,351 - $78,964	21,170 New	21,170 $7.81 Million
Q3 2021 Mar 22, 2023	SELL	$1.68 - $2.88 $3,360 - $5,760	-2,000 Reduced 9.45%	19,170 $32.4 Million
Q2 2021 Mar 22, 2023	SELL	$1.88 - $3.56 $23,500 - $44,500	-12,500 Reduced 59.05%	8,670 $24.2 Million
Q1 2021 Mar 22, 2023	SELL	$1.47 - $3.29 $18,375 - $41,125	-12,500 Reduced 59.05%	8,670 $19.4 Million
Q4 2020 Mar 22, 2023	SELL	$1.36 - $1.75 $19,040 - $24,500	-14,000 Reduced 66.13%	7,170 $10.4 Million
Q3 2020 Mar 22, 2023	SELL	$1.5 - $2.2 $27,450 - $40,260	-18,300 Reduced 86.44%	2,870 $4.31 Million
Q2 2020 Mar 24, 2023	BUY	$1.69 - $2.79 $338 - $558	200 Added 6.31%	3,370 $6.98 Million
Q1 2020 Mar 24, 2023	SELL	$1.59 - $3.35 $28,620 - $60,300	-18,000 Reduced 85.03%	3,170 $6.02 Million
Q4 2019 Mar 24, 2023	SELL	$2.68 - $4.85 $48,240 - $87,300	-18,000 Reduced 85.03%	3,170 $9.13 Million
Q3 2019 Mar 24, 2023	SELL	$4.1 - $9.0 $1,639 - $3,600	-400 Reduced 9.37%	3,870 $19.8 Million
Q2 2019 Mar 24, 2023	SELL	$5.15 - $7.92 $87,035 - $133,848	-16,900 Reduced 79.83%	4,270 $33.8 Million
Q1 2019 Mar 24, 2023	SELL	$5.1 - $6.71 $95,472 - $125,611	-18,720 Reduced 88.43%	2,450 $16.2 Million

Others Institutions Holding MRKR

# of Institutions

Shares Held

475K

Call Options Held

Put Options Held

View Full List

About Marker Therapeutics, Inc.

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $278M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

More about MRKR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Account

American Portfolios Advisors Marker Therapeutics, Inc. Transaction History